Stephens Has Raised Its Macquarie Infrastructure Cor (MIC) Stake; Ironwood Pharmaceuticals Has 1.05 Sentiment

March 15, 2018 - By Adrian Mccoy

Stephens Inc increased Macquarie Infrastructure Cor (MIC) stake by 50.76% reported in 2017Q3 SEC filing. Stephens Inc acquired 6,246 shares as Macquarie Infrastructure Cor (MIC)’s stock declined 1.43%. The Stephens Inc holds 18,550 shares with $1.34 million value, up from 12,304 last quarter. Macquarie Infrastructure Cor now has $3.27 billion valuation. The stock decreased 1.65% or $0.65 during the last trading session, reaching $38.56. About 351,117 shares traded. Macquarie Infrastructure Corporation (NYSE:MIC) has risen 11.18% since March 15, 2017 and is uptrending. It has underperformed by 5.52% the S&P500.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $2.37 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

Since January 1, 0001, it had 0 insider buys, and 7 selling transactions for $1.22 million activity.

Ecor1 Capital Llc holds 11.47% of its portfolio in Ironwood Pharmaceuticals, Inc. for 5.46 million shares. Bvf Inc Il owns 2.82 million shares or 5.65% of their US portfolio. Moreover, Sector Gamma As has 4.39% invested in the company for 1.83 million shares. The New York-based Bridger Management Llc has invested 2.4% in the stock. Senzar Asset Management Llc, a New York-based fund reported 507,000 shares.

Analysts await Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to report earnings on May, 14. They expect $-0.16 EPS, up 51.52% or $0.17 from last year’s $-0.33 per share. After $-0.14 actual EPS reported by Ironwood Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 14.29% negative EPS growth.

The stock increased 0.77% or $0.12 during the last trading session, reaching $15.67. About 97,022 shares traded. Ironwood Pharmaceuticals, Inc. (IRWD) has risen 57.40% since March 15, 2017 and is uptrending. It has outperformed by 40.70% the S&P500.

Ratings analysis reveals 25% of Ironwood Pharma’s analysts are positive. Out of 4 Wall Street analysts rating Ironwood Pharma, 1 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $13.0 while the high is $19.0. The stock’s average target of $16.25 is 3.70% above today’s ($15.67) share price. IRWD was included in 4 notes of analysts from September 27, 2016. WallachBeth Capital maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Tuesday, September 27 with “Hold” rating. The firm earned “Equal Weight” rating on Wednesday, February 22 by Barclays Capital. Mizuho maintained the shares of IRWD in report on Monday, October 10 with “Buy” rating. The rating was maintained by Wedbush with “Neutral” on Monday, October 24.

Stephens Inc decreased Price T Rowe Group Inc (NASDAQ:TROW) stake by 35,154 shares to 41,571 valued at $3.77 million in 2017Q3. It also reduced Cvs Health Corp (NYSE:CVS) stake by 15,492 shares and now owns 75,013 shares. V F Corp (NYSE:VFC) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.